Objective: This paper presents the results of a trans-cultural study looking at the possible differences in the symptomatology of Alzheimer's disease (AD) in people from Manchester, UK and Rawalpindi, Pakistan.
Methods: Two groups of people with AD (45 in each group) were recruited at the two sites. The participants and their carers were interviewed to investigate possible differences in demographics and symptomatology including cognition, depression, personality change and every day activities. The instrument used included the Mini Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Cornell Scale for Depression in Dementia (CSDD), The Brooks and McKinlay Personality Inventory and Informant Questionnaire on Cognitive Decline in the Elderly (IQ CODE).
Results: The data analysis showed that compared to people from Manchester the Pakistanis had lower literacy levels but similar cognitive deficits when MMSE scores were adjusted for education. They were however more depressed; they had a different profile of personality change since the onset of illness and their reported changes in activities of daily living were more severe.
Conclusion: The study has shown a number of possible cultural differences in affective symptoms, personality changes and every day activities. It highlights the need for developing mental health services for older people in Pakistan and making UK services more accessible for this growing community. Further research on service and care needs along with developing culturally sensitive instruments for assessing cognition, psychiatric symptoms, personality changes and daily activities is needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/gps.2544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role and Diagnostic Significance of Apolipoprotein D in Selected Neurodegenerative Disorders.
Diagnostics (Basel)
December 2024
Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 2c Mickiewicza Street, 15-233 Bialystok, Poland.
The World Health Organization in 2021 ranked Alzheimer's disease and other dementias as the seventh leading cause of death globally. Neurodegenerative disorders are progressive, intractable, and often fatal diseases. Early diagnosis may allow patients to enjoy prolonged survival with attenuated symptomatology because of early intervention.
View Article and Find Full Text PDFAlzheimer's disease and diabetes-associated cognitive dysfunction: the microglia link?
Metab Brain Dis
January 2025
Department of Pharmacy, the Second Affiliated Hospital of Shaoyang University, Shaoyang, Hunan, China.
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and the aggregation of tau protein, resulting in intense memory loss and dementia. Diabetes-associated cognitive dysfunction (DACD) is a complication of diabetes mellitus, which is associated with decreased cognitive function and impaired memory. A growing body of literature emphasize the involvement of microglia in AD and DACD.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of new H2S-releasing rivastigmine derivatives as neuroprotective molecules.
Eur J Med Chem
February 2025
Department of Pharmacy, University of Pisa, via Bonanno 6, 56126, Pisa, Italy; Centre for Instrumentation Sharing, University of Pisa (CISUP), Italy. Electronic address:
Alzheimer's disease (AD) represents one of the main challenges for the 21st century medical research as no disease-modifying agent has been successfully progressed to the market, while the number of people affected by AD is estimated to grow exponentially over the next years. The complex network of triggering factors involved in the insurgence and progression of AD can be rightly addressed as one of the main reasons behind the difficulty in identifying new pharmacological approaches. For this reason, the discovery and development of drugs endowed with pleiotropic activity remain the most valuable, but at the same time challenging, approaches to tackle down AD.
View Article and Find Full Text PDFImproving dementia prognostication in cognitively normal older adults: conventional versus novel approaches to modelling risk associated with neuropsychiatric symptoms.
Br J Psychiatry
December 2024
Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Article Synopsis
- Research identifies Mild Behavioral Impairment (MBI) as a significant indicator of future dementia risk in cognitively healthy individuals, distinguishing it from other neuropsychiatric symptoms (NPS).
- The study used data from the National Alzheimer’s Coordinating Center to compare three groups: those with MBI, those with NPS not classified as MBI, and those with no NPS, finding that MBI participants exhibited a much higher risk of developing dementia.
- Among individuals with MBI, there was a notable trend toward Alzheimer's disease, specifically highlighting a greater dementia incidence in those experiencing subjective cognitive decline compared to those without NPS.
Current Update on Promising New Anti-Alzheimer's Drugs in Different Phases of Clinical Development: Where Exactly Are We Lacking?
J Assoc Physicians India
December 2024
Assistant Professor, Department of Radiology, Vyas Medicity & Superspecialty Hospital, Jodhpur, Rajasthan, India.
The prevalence of Alzheimer's disease (AD) is rising with an aging population worldwide and is expected to surpass 130 million by 2050. India is no exception, but the true prevalence data on AD is not conclusive. By 2050, India will have almost 15% of the population aged 60 years or above.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!